Trade Protalix BioTherapeutics

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant enzyme, taliglucerase alfa, which has been approved by the U.S. Food and Drug Administration for the treatment of Gaucher's disease. Protalix BioTherapeutics established in 1993. It was founded by Youssef Shelpel, who received his Ph.D. in plant biochemistry from the Weizmann Institute in Israel and served in the Biology Department of the IDF Biological and Chemical Center. Philip Frost was one of the company's first and largest investors. Protalex has two Nobel Prize winners (chemistry) on its scientific advisory board, Roger Kornberg Ph.D. and M.D. Professor of Medicine. (Aaron Sishanover) in her early days Protalix works from a warehouse in the town of Kiryat Shmona in northern Israel. On July 19, 2005, Protalix Biotherapeutics announced the closure of a $5.3 million private placement of the C series of preferred shares. Protalix entered into a partnership agreement with Teva Pharmaceutical Industries in 2006 to develop two proteins and in 2009 signed a collaboration agreement with Pfizer to develop and market its alpha taliglocerase treatment. Also in 2009, Protalix reported that Frost and Sullivan provided the company with 2009 European Orphans Diseases